Adc Therapeutics Sa share price today

(ADCT)

Adc Therapeutics Sa share price is $2.07 & ₹175.33

$2.07

Market is closed - opens 8 PM, 05 Dec 2024

View live Adc Therapeutics Sa share price in Dollar and Rupees. Guide to invest in Adc Therapeutics Sa from India. Also see the sentimental analysis on Indian investors investing in Adc Therapeutics Sa. Get details on the Indian mutual funds that are investing in Adc Therapeutics Sa. Get Analyst recommendations and forecasts along with all the Adc Therapeutics Sa's financials.

Adc Therapeutics Sa share price movements

$2.06
$2.17
$2.07
0.72%
Downside
Day's Volatility :5.3%
Upside
4.61%
$0.94
$6.04
$2.07
54.54%
Downside
52 Weeks Volatility :84.42%
Upside
65.73%

Adc Therapeutics Sa Returns

Period	Adc Therapeutics Sa	Sector (Health Care)	Index (Russel 2000)
3 Months	-18.02%	-6.1%	0.0%
6 Months	-33.33%	1.4%	0.0%
1 Year	116.82%	11.4%	0.0%
3 Years	-88.43%	12.9%	-18.1%

Adc Therapeutics Sa Key Statistics

in dollars & INR

Market Capitalization	$234.0M
Revenue TTM	$70.7M
EBITDA	$-136.9M
Earnings Per Share (EPS)	$-2.39
Profit Margin	-300.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-705.53%

How to invest in Adc Therapeutics Sa from India?

It is very easy for Indian residents to invest directly in Adc Therapeutics Sa from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Adc Therapeutics Sa stock in both rupees (INR) and dollars (USD). Search for Adc Therapeutics Sa or ADCT on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Adc Therapeutics Sa or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Adc Therapeutics Sa shares which would translate to 0.409 fractional shares of Adc Therapeutics Sa as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Adc Therapeutics Sa

-20%

Period: Sep 5, 2024 to Dec 4, 2024. Change in 30 Days versus previous period

Search volume for Adc Therapeutics Sa on INDmoney from India has reduced in the last 30 days as on Dec 5, 2024. -20% less investors are searching Adc Therapeutics Sa in the last 30 days versus the previous period.

Global Institutional Holdings in Adc Therapeutics Sa

Redmile Group, LLC
16.21%
Prosight Management, LP
9.97%
Orbimed Advisors, LLC
4.69%
BlackRock Inc
3.68%
Morgan Stanley - Brokerage Accounts
3.14%
SILVERARC CAPITAL MANAGEMENT, LLC
1.86%

Analyst Recommendation on Adc Therapeutics Sa

Buy

83%Buy

16%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Adc Therapeutics Sa(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Adc Therapeutics Sa

What analysts predicted

Upside of 305.8%

Current:

$2.07

Target:

$8.40

Insights on Adc Therapeutics Sa

Increasing Revenue
Revenue is up for the last 2 quarters, 17.41M → 18.01M (in $), with an average increase of 3.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -36.54M → -43.96M (in $), with an average decrease of 20.3% per quarter
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.6% return, outperforming this stock by 136.8%

Adc Therapeutics Sa Financials in INR & Dollars

	FY21	Y/Y Change
Revenue	$33.9M	↑ 0.0%
Net Income	$-230.0M	↑ 0.0%
Net Profit Margin	-678.2%	↑ 0.0%

	FY21	Y/Y Change
Revenue	$33.9M	↑ 0.0%
Net Income	$-230.0M	↑ 0.0%
Net Profit Margin	-678.2%	↑ 0.0%

	FY22	Y/Y Change
Revenue	$209.9M	↑ 0.0%
Net Income	$-155.8M	↑ 0.0%
Net Profit Margin	-74.22%	↑ 0.0%

	FY22	Y/Y Change
Revenue	$209.9M	↑ 0.0%
Net Income	$-155.8M	↑ 0.0%
Net Profit Margin	-74.22%	↑ 0.0%

	FY23	Y/Y Change
Revenue	$69.6M	↑ 0.0%
Net Income	$-240.1M	↑ 0.0%
Net Profit Margin	-345.11%	↑ 0.0%

	FY23	Y/Y Change
Revenue	$69.6M	↑ 0.0%
Net Income	$-240.1M	↑ 0.0%
Net Profit Margin	-345.11%	↑ 0.0%

	Q2 FY23	Q/Q Change
Revenue	$19.3M	↑ 1.53%
Net Income	$-47.1M	↓ 20.71%
Net Profit Margin	-244.34%	↑ 68.56%

	Q3 FY23	Q/Q Change
Revenue	$14.5M	↓ 24.84%
Net Income	$-47.8M	↑ 1.46%
Net Profit Margin	-329.86%	↓ 85.52%

	Q4 FY23	Q/Q Change
Revenue	$16.8M	↑ 15.85%
Net Income	$-85.0M	↑ 77.86%
Net Profit Margin	-506.44%	↓ 176.58%

	Q1 FY24	Q/Q Change
Revenue	$18.1M	↑ 7.52%
Net Income	$-46.6M	↓ 45.19%
Net Profit Margin	-258.16%	↑ 248.28%

	Q2 FY24	Q/Q Change
Revenue	$17.4M	↓ 3.56%
Net Income	$-36.5M	↓ 21.59%
Net Profit Margin	-209.9%	↑ 48.26%

	Q3 FY24	Q/Q Change
Revenue	$18.0M	↑ 3.48%
Net Income	$-44.0M	↑ 20.32%
Net Profit Margin	-244.06%	↓ 34.16%

	FY21	Y/Y Change
Total Assets	$618.0M	↑ 0.0%
Total Liabilities	$451.9M	↑ 0.0%

	FY21	Y/Y Change
Total Assets	$618.0M	↑ 0.0%
Total Liabilities	$451.9M	↑ 0.0%

	FY22	Y/Y Change
Total Assets	$529.2M	↑ 0.0%
Total Liabilities	$440.4M	↑ 0.0%

	FY22	Y/Y Change
Total Assets	$529.2M	↑ 0.0%
Total Liabilities	$440.4M	↑ 0.0%

	FY23	Y/Y Change
Total Assets	$354.8M	↑ 0.0%
Total Liabilities	$503.0M	↑ 0.0%

	FY23	Y/Y Change
Total Assets	$354.8M	↑ 0.0%
Total Liabilities	$503.0M	↑ 0.0%

	Q2 FY23	Q/Q Change
Total Assets	$507.3M	↑ 8.47%
Total Liabilities	$515.9M	↑ 19.98%

	Q3 FY23	Q/Q Change
Total Assets	$466.9M	↓ 7.96%
Total Liabilities	$521.1M	↑ 1.01%

	Q4 FY23	Q/Q Change
Total Assets	$354.8M	↓ 24.01%
Total Liabilities	$503.0M	↓ 3.46%

	Q1 FY24	Q/Q Change
Total Assets	$308.0M	↓ 13.2%
Total Liabilities	$502.4M	↓ 0.12%

	Q2 FY24	Q/Q Change
Total Assets	$371.8M	↑ 20.72%
Total Liabilities	$503.4M	↑ 0.21%

	Q3 FY24	Q/Q Change
Total Assets	$349.1M	↓ 6.11%
Total Liabilities	$521.0M	↑ 3.49%

	FY21	Y/Y Change
Operating Cash Flow	$-233.4M	↑ 0.0%
Investing Cash Flow	$-6.7M	↑ 0.0%
Financing Cash Flow	$267.4M	↑ 0.0%

	FY21	Y/Y Change
Operating Cash Flow	$-233.4M	↑ 0.0%
Investing Cash Flow	$-6.7M	↑ 0.0%
Financing Cash Flow	$267.4M	↑ 0.0%

	FY22	Y/Y Change
Operating Cash Flow	$-136.8M	↑ 0.0%
Investing Cash Flow	$-2.5M	↑ 0.0%
Financing Cash Flow	$-593.0K	↑ 0.0%

	FY22	Y/Y Change
Operating Cash Flow	$-136.8M	↑ 0.0%
Investing Cash Flow	$-2.5M	↑ 0.0%
Financing Cash Flow	$-593.0K	↑ 0.0%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-36.8M	↑ 149.31%
Investing Cash Flow	$-661.0K	↑ 0.0%
Financing Cash Flow	$74.7M	↓ 38232.14%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-34.0M	↓ 7.63%
Investing Cash Flow	$-661.0K	↑ 0.0%
Financing Cash Flow	$-2.3M	↓ 103.09%

Adc Therapeutics Sa Technicals Summary

Sell

Neutral

Buy

Adc Therapeutics Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Adc Therapeutics Sa Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Adc Therapeutics Sa	-23.93%	-33.33%	116.82%	-88.43%	-92.18%
Regeneron Pharmaceuticals, Inc.	-8.02%	-23.83%	-8.78%	21.97%	108.5%
Biontech Se	7.55%	15.12%	15.65%	-58.12%	304.14%
Alnylam Pharmaceuticals, Inc.	-6.28%	69.46%	44.56%	42.94%	109.6%
Vertex Pharmaceuticals Incorporated	-1.5%	-4.08%	31.76%	127.12%	112.3%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Adc Therapeutics Sa	NA	NA	NA	0.0	-7.06	-0.21	NA	-1.78
Regeneron Pharmaceuticals, Inc.	18.55	18.55	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.23	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Adc Therapeutics Sa	Buy	$234.0M	-92.18%	NA	-300.0%
Regeneron Pharmaceuticals, Inc.	Buy	$83.0B	108.5%	18.55	33.61%
Biontech Se	Buy	$28.9B	304.14%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	109.6%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$120.6B	112.3%	32.84	-4.51%

About Adc Therapeutics Sa

adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.

Organization	Adc Therapeutics Sa
Employees	273
CEO	Dr. Ameet Mallik M.B.A., M.S.
Industry	Health Technology

Important FAQs about investing in Adc Therapeutics Sa from India :

What is Adc Therapeutics Sa share price today?

Adc Therapeutics Sa (ADCT) share price today is $2.07.

Can Indians buy Adc Therapeutics Sa shares?

Yes, Indians can invest in the Adc Therapeutics Sa (ADCT) from India.

With INDmoney, you can buy Adc Therapeutics Sa at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Adc Therapeutics Sa at zero transaction cost.

How can I buy Adc Therapeutics Sa shares from India?

It is very easy to buy Adc Therapeutics Sa from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Adc Therapeutics Sa be purchased?

Yes, you can buy fractional shares of Adc Therapeutics Sa with INDmoney app.

What are the documents required to start investing in Adc Therapeutics Sa stocks?

To start investing in Adc Therapeutics Sa, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.